Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$150,000.00
Azithromycin as add-on therapy in patients failing medical and surgical treatment for chronic rhinosinusitis: a double-blind, randomized, placebo-controlled trial
EF 2018-19
Résumé
Background
Chronic rhinosinusitis (CRS) is estimated to currently affect three million people in Canada alone, with most showing adequate response to standard medical and/or surgical therapy. Unfortunately, one in three patients with CRS will have disease persistence and require additional medical and surgical interventions. This not only affects the quality of life of patients but also represents an immense socioeconomic burden. Finding more effective alternatives is primordial. The first step is to identify patients that are at risk of failing standard therapy, and then targeting them for alternative therapy. The former was already completed by our team, allowing us to now focus on this high-risk population for additional therapy.
Primary Objective
Evaluate whether adding a macrolide, azithromycin, three times weekly is effective in not only controlling, but curing signs and symptoms of CRS in high-risk patients unresponsive to standard management after sinus surgery and nasal irrigations with corticosteroid respules (budesonide).
Study design
Patients meeting inclusion and exclusion criteria operated for CRS will receive budesonide nasal irrigations postoperatively. Patients with signs and symptoms of disease recurrence despite surgical and medical treatment will enter the randomized clinical trial. All patients included in the study will undergo thorough evaluations at every visit, looking at the symptom and surgical outcome, while also evaluating the genetic and bacterial evolution of the sinuses.
Long-term significance
Identifying a more personalized approach to the disease can lead to significant symptom alleviation, decreased need for additional medical and surgical interventions and an important socioeconomic gain. Furthermore, properly identifying and characterizing this population, as well as the immunomodulatory aspects of azithromycin in CRS can open future therapeutic avenues not only in rhinology but in respiratory diseases as a whole.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
396363
Name
Maniakas Anastasios
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Azithromycin as add-on therapy in patients failing medical and surgical treatment for chronic rhinosinusitis: a double-blind, randomized, placebo-controlled trial
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Chronic Rhinosinusitis; Clinical Trial; Corticosteroid Therapy; Double Blind Randomization; Endoscopic Sinus Surgery; Genotyping; Macrolide; Microbiome; Personalized Medicine
Abstract
Background
Chronic rhinosinusitis (CRS) is estimated to currently affect three million people in Canada alone, with most showing adequate response to standard medical and/or surgical therapy. Unfortunately, one in three patients with CRS will have disease persistence and require additional medical and surgical interventions. This not only affects the quality of life of patients but also represents an immense socioeconomic burden. Finding more effective alternatives is primordial. The first step is to identify patients that are at risk of failing standard therapy, and then targeting them for alternative therapy. The former was already completed by our team, allowing us to now focus on this high-risk population for additional therapy.
Primary Objective
Evaluate whether adding a macrolide, azithromycin, three times weekly is effective in not only controlling, but curing signs and symptoms of CRS in high-risk patients unresponsive to standard management after sinus surgery and nasal irrigations with corticosteroid respules (budesonide).
Study design
Patients meeting inclusion and exclusion criteria operated for CRS will receive budesonide nasal irrigations postoperatively. Patients with signs and symptoms of disease recurrence despite surgical and medical treatment will enter the randomized clinical trial. All patients included in the study will undergo thorough evaluations at every visit, looking at the symptom and surgical outcome, while also evaluating the genetic and bacterial evolution of the sinuses.
Long-term significance
Identifying a more personalized approach to the disease can lead to significant symptom alleviation, decreased need for additional medical and surgical interventions and an important socioeconomic gain. Furthermore, properly identifying and characterizing this population, as well as the immunomodulatory aspects of azithromycin in CRS can open future therapeutic avenues not only in rhinology but in respiratory diseases as a whole.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Maniakas, Anastasios
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~